SPARC Announces U.S. FDA Acceptance of NDA for TaclantisTM (Paclitaxel Injection Concentrate for Suspension) for Filing and Regulatory Review

HitGen and SPARC Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration

Schrödinger and SPARC Announce Collaboration to Accelerate Neurodegeneration Drug Development Program

SPARC Announces Top-line Results of Pivotal Bioequivalence Study for Paclitaxel Injection Concentrate for Suspension

Sun Pharma and SPARC Announce US FDA Approval of XELPROS™ to Treat Open-angle Glaucoma or Ocular Hypertension

Audio playback of Investors Presentation

Update on R&D Pipeline

SPARC Provides Update on Pivotal Phase III Studies of Baclofen GRS for Treatment of Spasticity in Patients with Multiple Sclerosis

SPARC Announces Top-line Results of Pivotal Peak Inspiratory Flow (PIF) study and Low Dose Pharmacokinetic (PK) Study for Salmeterol – Fluticasone Dry Powder Inhaler (SPARC DPI)

Announcement - Receipt of reclassification approval from BSE